Hayley Virgil | Authors


Axi-Cel Shows Activity in Relapsed/Refractory DLBCL Regardless of Chemo Sensitivity

February 22, 2021

Data from patients with relapsed/refractory diffuse large B-cell lymphoma treated with axicabtagene ciloleucel showed that post-chimeric antigen receptor T outcomes may not correlate with responsiveness observed with treatment received immediately prior.

High CR Achieved With Addition of N-803 to BCG in BCG-Unresponsive NMIBC CIS

February 13, 2021

In patients with non-muscle invasive bladder cancer carcinoma in-situ who were unresponsive to Bacillus Calmette-Guerin, the addition of N-803 induced a high rate of complete responses, findings from a cohort of the phase 2/3 QUILT-3.032 study showed.

PROs Show Adjuvant Osimertinib Maintains HRQoL in EGFR+ NSCLC

January 31, 2021

Patient-reported outcomes from the phase 3 ADAURA trial showed that adjuvant osimertinib maintained health-related quality of life compared with placebo in patients with EGFR-positive non–small cell lung cancer.

Osimertinib Plus Savolitnib May Address MET Resistance in EGFR+, MET-Amplified NSCLC

January 28, 2021

Patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer and MET resistance treated with osimertinib in combination with savolitinib may be able to overcome resistance, according to final analysis findings.